Skip to main
CBLL

Ceribell Inc (CBLL) Stock Forecast & Price Target

Ceribell Inc (CBLL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CeriBell is a medical technology company that has developed the Ceribell System, a point-of-care EEG platform that uses artificial intelligence to rapidly diagnose and monitor neurological conditions. The company recently received FDA approval for its delirium monitoring solution, and is also exploring new indications such as ischemic stroke. With a healthy financial profile and a strong pipeline, CeriBell is well-positioned for long-term growth and has the potential to become a leader in the medical technology industry.

Bears say

CeriBell is a MedTech company with a Buy rating, but there are risks to consider such as geopolitical tensions and potential tariffs that could negatively impact the company's gross margins. While the Ceribell System has gained commercial traction and the company has a healthy financial profile, it is still in the early stages of commercialization and faces competition in the market. Additionally, the company's future growth is heavily reliant on its ability to gain new accounts and maintain utilization at existing accounts.

Ceribell Inc (CBLL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ceribell Inc (CBLL) Forecast

Analysts have given Ceribell Inc (CBLL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Ceribell Inc (CBLL) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ceribell Inc (CBLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.